Abstract
Objective: Thymic carcinoma is treated by the same guidelines used for thymoma, despite having a more aggressive histologic appearance and clinical course. Method: To evaluate the outcome of treatment, patients undergoing treatment including surgery at the National Cancer Center Hospital East were reviewed and reported with descriptions of postoperative pathologic stages based on Masaoka staging.Results: Six Japanese patients — 2 men and 4 women with a median age of 59 years (range: 23–67) — underwent treatment, including surgery. The histologic type of tumor was squamous cell carcinoma in 4,1 of which was associated with invasive thymoma; adenosquamous carcinoma associated with thymoma in 1; and lymphoepitheliomalike carcinoma in 1. Four of the 6 patients survived — 2 stage II were alive and well with no evidence of disease 69 months and 44 months after surgery; 1 stage III was alive with the disease 44 months after preoperative chemotherapy and subsequent surgery; and 1 stage III was alive with multiple pulmonary metastases 17 months after surgery. A stage IVa died of the tumor 48 months after preoperative chemotherapy and subsequent surgery, while 1 stage III died of the tumor 35 months after surgery.Conclusion: The outcome of thymic carcinoma treatment must be reported using the same histologie typing and staging. Further study is warranted to define precise treatment strategy for this disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shimosato M, Mukai K. Tumors of the thymus and related lesions. In: Rosai J, ed. Atlas of Tumor Pathology. Third series. Fascicle 21. Tumors of Mediastinum. Washington, D.C.: Armed Forces Institute of Pathology, 1997: 33–148.
Suster S, Rosai J. Thymic carcinoma: a clinicopathologic study of 60 cases. Cancer 1991; 67: 1025–32.
Committee of Science. Thoracic and cardiovascular surgery in Japan during 1997. Annual report, Japanese Association for Thoracic Surgery. Jpn J Thorac Cardiovasc Surg 1999; 47: 237–51.
Kirchner T, Schalke B, Buchwald J, Ritter M, Marx A, Mueller-Hermelink H. Well-differentiated thymic carcinoma: an organotypical low-grade carcinoma with relationship to cortical thymoma. Am J Surg Pathol 1992; 16: 1153–69.
Monden Y, Nakahara K, Iioka S, Nanjo S, Ohno K, Fujii Y, et al. Recurrence of thymoma: clinicopathological features, therapy, and prognosis. Ann Thorac Surg 1985; 39: 165–9.
Truong LD, Mody DR, Cagle PT, Jackson-York GL, Schwartz MR, et al. Thymic carcinoma: a clinicopathological study of 13 cases. Am J Surg Pathol 1990; 14: 151–66.
Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol 1978; 9: 495–515.
Snover DC, Levine GD, Rosai J. Thymic carcinoma: five distinctive histological variants. Am J Surg Pathol 1982; 6: 451–70.
Wick MR, Weiland LH, Scheithauer BW, Bernatz PE. Primary thymic carcinomas. Am J Surg Pathol 1982; 6: 613–30.
Weide LG, Ulbright TM, Loehrer PJ Sr, Williams SD. Thymic carcinoma. A distinct clinical entity responsive to chemotherapy. Cancer 1993; 71: 1219–23.
Hsu CP, Chen CY, Chen CL, Lin CT, Hsu NY, Wang JH, et al. Thymic carcinoma: ten years’ experience in twenty patients. J Thorac Cardiovasc Surg 1994; 107: 615–20.
Blumberg D, Burt ME, Bains MS, Downey RJ, Martini N, Rusch V, et al. Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg 1998; 115: 303–9.
Masaoka A, Yamakawa Y, Fujii Y. Well-differentiated thymic carcinoma: Is it thymic carcinoma or not? (Letter to the Editor) J Thorac Cardiovasc Surg 1999; 117: 628–30.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takahashi, K., Yoshida, J., Nishimura, M. et al. Thymic carcinoma. Jpn J Thorac Caridovasc Surg 48, 494–498 (2000). https://doi.org/10.1007/BF03218184
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03218184